scholarly journals Mechanism of the Lymph Node Metastasis in Human Esophageal Cancer. Epidermal Growth Factor Causes Dysfunction of Cadherin-mediated Cell-cell Adheion.

1996 ◽  
Vol 29 (4) ◽  
pp. 858-862
Author(s):  
Hitoshi Shiozaki ◽  
Masatoshi Inoue ◽  
Shigeyuki Tamura ◽  
Yuuichiro Doki ◽  
Takatoshi Kadowaki ◽  
...  
PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252646
Author(s):  
Margot Geens ◽  
Sofie Stappers ◽  
Heleen Konings ◽  
Benedicte Y. De Winter ◽  
Pol Specenier ◽  
...  

In this study, we investigated serum epidermal growth factor (EGF) in an oncological population of head- and neck and pulmonary neoplasms and whether serum EGF could serve as a prognostic marker of survival and as a predictive marker for treatment response to platinum-based chemotherapy. A total of 59 oncological patients and a control group of age- and sex-matched healthy volunteers were included in this study. Pre-treatment serum EGF from both groups was determined. Patient’s and tumour characteristics and mortality were recorded during a 5-year follow up period. Baseline serum EGF significantly differed between the oncological patients and the healthy volunteers (p<0.001). Serum EGF was associated with lymph node metastasis (p = 0.004) but not with sex (p = 0.753), age (p = 1.00), TNM stage (p = 0.191) or tumour size (p = 0.077). Neither serum EGF (p = 0.81) nor age (p = 0.55) showed an effect on the patient’s survival. Tumour location was significantly associated with overall 5-year survival (p = 0.003). The predictive capacity of serum EGF of response to chemotherapy was limited (AUC = 0.606), a sensitivity of 80% and a specificity of 56% was observed resulting in a likelihood ratio of a positive and negative test equal to 1.81 and 0.36, respectively. In conclusion, serum EGF levels are 5.5 times higher in an oncological population compared to a control group. Within the oncological population, low serum EGF values are associated with the presence of lymph node metastasis. Further investigation is necessary to determine if the serum EGF levels could serve as a diagnostic biomarker.


2013 ◽  
Vol 133 (1) ◽  
pp. 230-238 ◽  
Author(s):  
Andreas Bracher ◽  
Ana Soler Cardona ◽  
Stefanie Tauber ◽  
Astrid M. Fink ◽  
Andreas Steiner ◽  
...  

2007 ◽  
Vol 17 (2) ◽  
pp. 492-496 ◽  
Author(s):  
S. Kang ◽  
J. W. Kim ◽  
N.-H. Park ◽  
Y.-S. Song ◽  
S.-Y. Park ◽  
...  

Cervical cancer, the second most common malignancy in women worldwide, is almost invariably associated with infection by human papillomavirus (HPV). However, although many women are infected with high-risk types of HPV, only a subset of infected women will ever develop cervical cancer. Therefore, host genetic factor may play a role in cervical carcinogenesis. Alterations in epidermal growth factor receptor (EGFR) are common events in cervical cancer. Therefore, we hypothesized that a functional polymorphism in the 5′ untranslated region of the epidermal growth factor (EGF) gene, a natural ligand of the EGFR, may play a role in the cervical carcinogenesis and tumor invasiveness. We assessed the possible association between EGF +61 A/G polymorphism and cervical cancer risk in a hospital-based case–control study among 337 Korean women (168 cases, 169 age-matched controls). The frequencies of EGF +61 allele and genotype were not different between cases and controls. We observed increasing trend of lymph node metastasis from A/A homozygous genotype toward G/G homozygous genotype. We did not find any evidence that EGF +61 A/G polymorphism was associated with individual susceptibility of cervical cancer. However, although it was not statistically significant, the increasing trend of lymph node metastasis according to EGF genotype suggests the possibility that individual variance of EGF expression may be associated with cervical cancer invasiveness. We also confirmed that there exists striking ethnic heterogeneity of EGF genotype between Caucasian and East Asian population


Sign in / Sign up

Export Citation Format

Share Document